Incidence of and Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Thoracic Malignancies: A Prospective Multicenter Study. (PubMed, Oncologist) - Sep 24, 2026 - "In this prospective real-world cohort, the incidence of ICI-P was relatively high, and ILAs detected by HRCT, heavy smoking history, and treatment with a PD-1 inhibitor alone or in combination with cytotoxic chemotherapy were identified as independent risk factors."
Checkpoint inhibition • Clinical • Journal • Inflammation • Oncology • Pneumonia • Thoracic Cancer
|
|
Dai Hashimoto; Hideki Yasui; Hironao Hozumi; Hiroyuki Matsuda; Kazuhiro Asada; Kazuki Furuhashi; Keigo Koda; Koji Nishimoto; Kumi Ozaki; Masaki Ikeda; Masaki Sato; Masato Fujii; Masato Karayama; Mitsuru Niwa; Nao Inami; Naoki Inui; Noriyuki Enomoto; Satoshi Goshima; Shintaro Ichikawa; Shun Matsuura; Takafumi Koyauchi; Takafumi Suda; Takashi Matsui; Tomoyuki Fujisawa; Yasuhiro Ito; Yoshihiro Kitahara; Yusuke Inoue; Yusuke Kaida; Yuzo Suzuki
|